MA53841A - Inhibiteurs pde9 de pyrazolopyrimidine - Google Patents

Inhibiteurs pde9 de pyrazolopyrimidine

Info

Publication number
MA53841A
MA53841A MA053841A MA53841A MA53841A MA 53841 A MA53841 A MA 53841A MA 053841 A MA053841 A MA 053841A MA 53841 A MA53841 A MA 53841A MA 53841 A MA53841 A MA 53841A
Authority
MA
Morocco
Prior art keywords
pyrazolopyrimidine
pde9 inhibitors
pde9
inhibitors
pyrazolopyrimidine pde9
Prior art date
Application number
MA053841A
Other languages
English (en)
Inventor
Ashok Arasappan
Jason M Cox
John S Debenham
Zhuyan Guo
Jiafang He
Zahid Hussain
Zhong Lai
Derun Li
Dongfang Meng
Subharekha Raghavan
Sriram Tyagarajan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA53841A publication Critical patent/MA53841A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA053841A 2017-06-08 2018-06-06 Inhibiteurs pde9 de pyrazolopyrimidine MA53841A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516903P 2017-06-08 2017-06-08
US201862665840P 2018-05-02 2018-05-02

Publications (1)

Publication Number Publication Date
MA53841A true MA53841A (fr) 2021-09-22

Family

ID=62779024

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053841A MA53841A (fr) 2017-06-08 2018-06-06 Inhibiteurs pde9 de pyrazolopyrimidine

Country Status (13)

Country Link
US (2) US10934294B2 (fr)
EP (1) EP3634964B1 (fr)
JP (1) JP2020523309A (fr)
KR (1) KR20200013758A (fr)
CN (1) CN111051308A (fr)
AU (1) AU2018281131B2 (fr)
BR (1) BR112019025813A2 (fr)
CA (1) CA3064938A1 (fr)
MA (1) MA53841A (fr)
MX (1) MX2019014597A (fr)
RU (1) RU2019144010A (fr)
TW (1) TW201902898A (fr)
WO (1) WO2018226771A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111051308A (zh) 2017-06-08 2020-04-21 默沙东公司 吡唑并嘧啶pde9抑制剂
EP3893881A4 (fr) * 2018-12-12 2022-08-17 Merck Sharp & Dohme Corp. Inhibiteurs de pde9 au pyrazolopyrimidine cyclobutyle
CN114773256B (zh) * 2022-03-23 2024-05-03 中国农业大学 一种4-氰基哌啶的合成方法
CN117582909B (zh) * 2024-01-19 2024-04-02 天津凯莱英医药科技发展有限公司 一种连续生产5-单硝酸异山梨酯的系统和方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE71183B1 (en) 1988-12-27 1997-01-29 Takeda Chemical Industries Ltd Guanidine derivatives their production and insecticides
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
WO2002009713A2 (fr) 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Inhibiteurs selectifs de pde 2 comme medicaments ameliorant la perception
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
CA2612176C (fr) 2005-06-14 2015-02-17 Aska Pharmaceutical Co., Ltd. Derives de l'acide dihydrothieno[2,3-d]pyrimidine-6-carboxylique en tant qu'inhibiteurs de pde9
CA2680789C (fr) 2006-03-28 2016-02-16 Atir Holding S.A. Composes heterocycliques et leurs utilisations dans le traitement de troubles sexuels
KR101419075B1 (ko) 2006-08-08 2014-07-11 아스카 세이야쿠 가부시키가이샤 퀴나졸린 유도체
EP2103613B1 (fr) 2006-12-13 2016-02-17 ASKA Pharmaceutical Co., Ltd. Dérivé de quinoxaline
ME00954B (fr) 2007-05-11 2012-06-20 Pfizer Composés amino-hétérocycliques
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
AP2011005672A0 (en) 2008-09-08 2011-04-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of CNS disorders.
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
NZ594567A (en) 2009-03-31 2013-12-20 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TW201118099A (en) 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
WO2012020022A1 (fr) * 2010-08-12 2012-02-16 Boehringer Ingelheim International Gmbh Dérivés de 6-cycloalkyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one et leurs utilisations en tant qu'inhibiteurs de pde9a
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN106905324B (zh) 2011-10-10 2018-09-25 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
KR101706216B1 (ko) 2012-04-03 2017-02-13 한화테크윈 주식회사 고밀도 삼차원 영상 재구성 장치 및 방법
WO2014024125A1 (fr) 2012-08-08 2014-02-13 Celon Pharma S.A. Dérivés pyrazolo[4,3-d]pyrimidin-7(6h)-one comme inhibiteurs de pde9
US10174032B2 (en) 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
WO2016191935A1 (fr) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Composés 6-alkyle dihydropyrazolopyrimidinone utilisés en tant qu'inhibiteurs de pde2
EP3313852B1 (fr) 2015-06-25 2021-01-20 Merck Sharp & Dohme Corp. Composés bicycliques pyrazolo/imidazolo substitués en tant qu'inhibiteurs de pde2
WO2017000276A1 (fr) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Composés hétérocycliques bicycliques utilisés en tant qu'inhibiteurs de pde2
WO2017019724A1 (fr) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Phénylcyanoquinolinones utiles en tant qu'inhibiteurs de pde9
US10370337B2 (en) 2015-07-29 2019-08-06 Merck, Sharp & Dohme Corp. Oxy-cyanoquinolinone PDE9 inhibitors
US10376504B2 (en) 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors
CN111051308A (zh) * 2017-06-08 2020-04-21 默沙东公司 吡唑并嘧啶pde9抑制剂

Also Published As

Publication number Publication date
US20180354955A1 (en) 2018-12-13
KR20200013758A (ko) 2020-02-07
EP3634964A1 (fr) 2020-04-15
US11028092B2 (en) 2021-06-08
AU2018281131B2 (en) 2022-01-20
WO2018226771A1 (fr) 2018-12-13
US20200140445A1 (en) 2020-05-07
JP2020523309A (ja) 2020-08-06
US10934294B2 (en) 2021-03-02
CA3064938A1 (fr) 2018-12-13
TW201902898A (zh) 2019-01-16
BR112019025813A2 (pt) 2020-07-07
RU2019144010A3 (fr) 2021-10-01
MX2019014597A (es) 2020-02-05
RU2019144010A (ru) 2021-07-13
CN111051308A (zh) 2020-04-21
AU2018281131A1 (en) 2019-12-05
EP3634964B1 (fr) 2022-02-23

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
MA52814A (fr) Inhibiteurs de bromodomaine
MA52812A (fr) Inhibiteurs de sarm1
MA44006A (fr) Inhibiteur pde1
DK3681884T3 (da) Rad51-inhibitorer
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
MA47301A (fr) Inhibiteurs sélectifs de jak1
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
MA53841A (fr) Inhibiteurs pde9 de pyrazolopyrimidine
MA52809A (fr) Inhibiteurs de sarm1
MA52813A (fr) Inhibiteurs de sarm1
IT201700032614A1 (it) Veicolo
MA51611A (fr) Inhibiteurs de pi4kiiibêta
CL2018000577S1 (es) Automóvil
DK3403877T3 (da) Anhænger
DE102017126475A8 (de) Fahrzeug
DK3519419T3 (da) Beta-lactamase-inhibitorer
DK3481826T3 (da) Tyrosinkinaseinhibitorer
MA44607A (fr) Inhibiteurs de kinase
DK3710457T3 (da) Immunproteasomhæmmere
ES1160610Y (es) Tampón
DK3720840T3 (da) Cathepsinhæmmere
DK3480087T3 (da) Opdelt anhænger